LAMEA Oncology/Anti-cancer Drugs Market Size, Share, and Trends 2025 to 2034

LAMEA Oncology/Anti-Cancer Drugs Market Size and Trends

The global LAMEA oncology/ant-cancer drugs market size is calculated at USD 10.55 billion in 2024, grow to USD 11.41 billion in 2025, and is projected to reach around USD 23.01 billion by 2034, and growing at a CAGR of 8.11% from 2025 to 2034. The market is growing due to rising cancer prevalence and increasing access to healthcare services across emerging economies. Government initiatives and expanding healthcare infrastructure are also boosting demand for advanced cancer therapies.

LAMEA Oncology/Anti-Cancer Drugs Market Key Takeaways

• Latin America dominated the LAMEA oncology/anti-cancer drugs market in 2024.
• The Middle East is expected to grow at the highest CAGR in the market during the forecast period.
• By therapeutic model, the chemotherapy segment dominated the market.
• By therapeutic model, the immunotherapy (biologics therapy) segment is expected to grow at the fastest CAGR in the market during the studied years.
• By cancer type, the blood cancer segment held the largest market share.
• By cancer type, the breast cancer segment is expected to grow at the fastest CAGR in the market during the studied years.

How is the LAMEA Oncology/Anti-Cancer Drugs Market Evolving?

LAMEA oncology/ant-cancer drugs are medications used to treat cancer in Latin America, the Middle East, and Africa. These drugs work by targeting and destroying cancer cells, stopping their growth, or enhancing the body’s immune system to fight cancer, aiming to improve survival and quality of life for patients. LAMEA oncology/ant-cancer drugs market is evolving due to increasing cancer awareness, better diagnostic facilities, and growing availability of advanced therapies like immunotherapy and targeted treatments. Governments and the private sector are investing more healthcare infrastructure, expanding access to modern cancer care. Additionally, pharmaceutical companies are strengthening their presence through partnerships and clinical trials, making innovative treatment more accessible. This progress is steadily improving cancer management and patient outcomes across LAMEA.

How Can AI Affect the LAMEA Oncology/Anti-Cancer Drugs Market?

AI is transforming the market by enhancing early cancer detection, accelerating drug discovery, and improving personalized treatment planning. It helps analyze vast patient data to identify effective therapies, predict treatment responses, and reduce trial timelines. AI-powered tools also support remote monitoring and clinical decision-making, especially in underserved areas. As healthcare systems in LAMEA modernize, AI integration is boosting efficiency, access to care, and overall cancer treatment outcomes across the region.

Report Scope of LAMEA Oncology/Anti-Cancer Drugs Market

Market Dynamics

Driver

Rising Burden of Cancer

The rising burden of cancer in the LAMEA oncology/anti-cancer drugs market as it leading to increased demand for effective treatment and early interventions. Factors such as urbanization, aging population, and lifestyle changes contribute to higher cancer incidence. This growing need pushes healthcare systems to invest in better diagnostic tools and innovative therapies. Consequently, pharmaceutical companies are expanding their presence in the region, introducing advanced drugs to meet the escalating treatment requirements.

• For Instance, In March 2024, the International Blantyre Cancer Centre was inaugurated to address the country’s rising cancer burden, with over 17,000 new cases reported annually. This development has led to a notable increase in the local demand for oncology and anti-cancer drugs.

Restraint

Limited Access to Advanced Healthcare Infrastructure and High Treatment Costs

High treatment costs and limited infrastructure hinder the LAMEA oncology/anti-cancer drugs market by reducing patient access to timely and effective care. Many healthcare systems in the region lack consistent drug supply chains, specialized cancer units, and advanced diagnostic tools. As a result, patients often face delays or receive incomplete treatment, leading to poorer outcomes. This discourages investment in innovative therapies and limits the reach of pharmaceutical companies, ultimately slowing down overall market development and accessibility.

Opportunity

Expansion of Clinical Trials and Local Drug Manufacturing

Expanding clinical trials and boosting local drug manufacturing in the LAMEA oncology market create long-term opportunities by encouraging innovation and improving drug accessibility. Regional trials help gather relevant patient data, leading to faster approvals and more effective therapies. Meanwhile, local manufacturing reduces supply chain delays and enhances affordability. This not only supports timely cancer care but also strengthens the region's pharmaceutical capabilities, positioning LAMEA as a growing hub for oncology research and treatment development.

• For Instance, In April 2025, ANMAT shortened clinical trial approval time from 160 to 70 business days. This regulatory shift is expected to triple oncology trials, boosting access to advanced cancer therapies and strengthening Argentina’s role in regional research.

Segmental Insights

How Does the Chemotherapy Segment Dominate the LAMEA Oncology/Anti-cancer Drugs Market in 2024?

Chemotherapy leads the market because it has long been the standard treatment and is widely accepted by healthcare providers. Unlike newer therapies that require specialized equipment or diagnostics, chemotherapy can be administered in basic clinical settings. Its broad-spectrum effectiveness across multiple cancer types and consistent supply through government and donor-funded programs make it accessible, especially in low-and middle-income countries within the region, maintaining its dominance in cancer treatment.

Immunotherapy is gaining momentum in the LAMEA oncology/anti-cancer drugs market because of its ability to boost the body’s natural defenses to fight cancer more effectively. Unlike conventional treatment, it offers long-term benefits and improved survival rates in hard-to-treat cancer. The rise in clinical trials, supportive regulatory frameworks, and partnerships with global biotech firms are accelerating its presence. As patient preference shifts towards personalized and less toxic treatment, immunotherapy is emerging as the most promising therapeutic option in the region.

How Does the Squamous Cell Carcinoma Segment Dominate the LAMEA Oncology/Anti-cancer Drugs Market?

Blood cancer leads the market because of growing awareness of novel therapies like monoclonal antibodies and CAR-T treatments. These cancers often require long-term treatment, increasing drug consumption. International collaboration and aid programs have also focused on strengthening hematologic cancer care in low-resource settings, improving patient access. As treatment protocols evolve and survival rates improve, the demand for blood cancer therapies continues to outpace other cancer types in the region.

Breast cancer is projected to grow rapidly in the market as lifestyle changes, urbanization, and delayed childbirth lead to higher case numbers. Expanding women's health programs and better access to diagnostic tools are enabling earlier intervention. The introduction of affordable biosimilar targeted therapies is also making advanced treatment options more accessible. Combined with increased public health focus on female cancers, these factors are accelerating growth in the breast cancer treatment segment across the region.

Regional Insights

How is North America Contributing to the Expansion of the LAMEA Oncology/Anti-cancer Drugs Market?

In 2024, Latin America led the market due to growing pharmaceutical infrastructure, increased patient awareness, and greater involvement in international research collaborations. The presence of leading cancer institutes and rising demand for innovative therapies supported faster adoption of new treatments. Government initiatives focused on expanding universal healthcare access and early cancer screening also played a key role, allowing broader reach of oncology drugs across both urban and semi-urban populations in the region.

How is the Asia Pacific Accelerating the LAMEA Oncology/Anti-cancer Drugs Market?

The Middle East is set to witness strong growth in the oncology anti-cancer drugs market as awareness of cancer symptoms and screening steadily increases. Investments in research, early diagnosis, and the introduction of biologics and precision therapies are improving treatment outcomes. Countries like the UAE and Saudi Arabia are enhancing cancer care through tech-enabled healthcare models and international collaborations. These developments are boosting treatment capacity and access, positioning the region for accelerated growth in oncology drug demand.

Some of The Prominent Players in The LAMEA Oncology/Anti-cancer drugs Market Include:

• Roche
• Novartis
• AstraZeneca
• Pfizer
• Bristol Myers Squibb

Recent Development in the LAMEA Oncology/Anti-cancer Drugs Market

• In 2024, Brazil became a key center for oncology drug development, especially in late-stage clinical trials and biosimilars. Major global pharmaceutical firms like Roche and Pfizer expanded their involvement in the country's clinical research sector, highlighting Brazil's growing role in advancing cancer treatments through strategic trial activities.
  
  
• In 2024, Synthon, a leading European pharmaceutical company, introduced two new oncology treatments in Mexico—a biosimilar of bevacizumab for colorectal cancer and a bioequivalent of abiraterone for prostate cancer. With rising cancer cases—around 15,000 new colorectal and over 25,000 prostate cancer diagnoses annually in Mexico—these therapies aim to reduce mortality and improve patients’ quality of life across the country.

Segments Covered in the Report

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2034. For this study, Nova one advisor, Inc. has segmented the LAMEA Oncology/Anti-cancer drugs Market.

By Therapeutic Modalities

• Chemotherapy
• Targeted therapy
• Immunotherapy (biologic therapy)
• Other

By Cancer Types

• Blood cancer
• Breast cancer
• Gastrointestinal cancer
• Prostate cancer
• Respiratory/lung cancer
• Skin cancer
• Other cancer

By Regional

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa (MEA)